# Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy

> **NCT01762852** · PHASE2 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Glomerulonephritis, Membranous

## Interventions

- **DRUG:** Belimumab 10 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01762852
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-04
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn due to difficulties in to recruiting due to competing studies, changing treatment practices, unavailability of eligible study population
- **Last updated:** 2017-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01762852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01762852, "Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01762852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*